We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+47.65%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$600M
AUM Growth
+$162M
Cap. Flow
+$3.3M
Cap. Flow %
0.55%
Top 10 Hldgs %
72.6%
Holding
57
New
6
Increased
11
Reduced
18
Closed
13

Top Buys

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$18.3M
2
CDXS icon
Codexis
CDXS
+$16.4M
3
LQDA icon
Liquidia Corp
LQDA
+$15M
4
DNA icon
Ginkgo Bioworks
DNA
+$8.22M
5
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$3.51M

Top Sells

Rank Stock Value
1
CPRX
Catalyst Pharmaceutical
CPRX
+$9.78M
2
FDMT icon
4D Molecular Therapeutics
FDMT
+$7.26M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$7.19M
4
CYTK icon
Cytokinetics
CYTK
+$6.87M
5
NTLA icon
Intellia Therapeutics
NTLA
+$4.88M

Sector Composition

Rank Sector Weight
1 Healthcare 98.64%
2 Miscellaneous 1.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
26
Cytokinetics
CYTK
$10.8B
$3.98M 0.66%
75,300
-123,200
-62% -$6.87M
GOSS icon
27
Gossamer Bio
GOSS
$83.2M
$3.71M 0.62%
3,665,010
-244,990
-6% -$236K
ZNTL icon
28
Zentalis Pharmaceuticals
ZNTL
$367M
$3.56M 0.59%
+967,000
New +$3.51M
TARA icon
29
Protara Therapeutics
TARA
$236M
$3.08M 0.51%
1,681,154
-623,108
-27% -$1.28M
RZLT icon
30
Rezolute
RZLT
$480M
$2.26M 0.38%
+466,563
New +$2.14M
CPRX
31
DELISTED
Catalyst Pharmaceutical
CPRX
$2.24M 0.37%
112,500
-527,500
-82% -$9.78M
ABCL icon
32
AbCellera Biologics
ABCL
$4.02B
$2.08M 0.35%
800,000
+600,000
+300% +$1.66M
LYEL icon
33
Lyell Immunopharma
LYEL
$358M
$1.93M 0.32%
69,750
-13,750
-16% -$404K
ALLK
34
DELISTED
Allakos
ALLK
$1.57M 0.26%
2,407,600
-372,400
-13% -$270K
RLMD icon
35
Relmada Therapeutics
RLMD
$482M
$1.56M 0.26%
480,000
-120,000
-20% -$389K
PEPG icon
36
PepGen
PEPG
$213M
$1.53M 0.26%
+179,200
New +$2.12M
RVNC
37
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.43M 0.24%
+275,000
New +$1.37M
SYRS
38
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.41M 0.23%
654,943
-210,500
-24% -$756K
JBIO
39
Jade Biosciences
JBIO
$1.35B
$920K 0.15%
12,571
– –
RGLS
40
DELISTED
Regulus Therapeutics
RGLS
$840K 0.14%
535,000
-940,000
-64% -$1.56M
IBIO icon
41
iBio
IBIO
$69.5M
$833K 0.14%
375,000
– –
ADGM
42
Adagio Medical Holdings
ADGM
$11.6M
$285K 0.05%
+110,571
New +$526K
ALGS icon
43
Aligos Therapeutics
ALGS
$44.1M
– –
-50,400
Closed -$441K
DSGN icon
44
Design Therapeutics
DSGN
$954M
– –
-205,000
Closed -$687K
FDMT icon
45
4D Molecular Therapeutics
FDMT
$824M
– –
-345,750
Closed -$7.26M
FULC icon
46
Fulcrum Therapeutics
FULC
$294M
– –
-285,000
Closed -$1.77M
IOVA icon
47
Iovance Biotherapeutics
IOVA
$3.74B
– –
-897,000
Closed -$7.19M
KPTI icon
48
Karyopharm Therapeutics
KPTI
$44M
– –
-95,000
Closed -$1.24M
LXRX icon
49
Lexicon Pharmaceuticals
LXRX
$1.03B
– –
-1,875,000
Closed -$3.15M
NTLA icon
50
Intellia Therapeutics
NTLA
$1.84B
– –
-218,000
Closed -$4.88M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2024 Portfolio in Review

As of Q3 2024, Opaleye Management held 57 positions worth $600M, up 37% from $438M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Opaleye Management's Q3 2024 filing shows 6 new, 11 increased, 18 reduced and 13 closed positions. Its largest new stake was Ginkgo Bioworks: 820,202 shares worth $6.68M. The largest sale was Catalyst Pharmaceutical, an estimated $9.78M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q3 2024 buy was Ginkgo Bioworks: 820,202 shares worth $6.68M.
  • Opaleye Management added most to Arvinas in Q3 2024, an estimated $18.3M increase.
  • Opaleye Management's biggest Q3 2024 reduction was Catalyst Pharmaceutical, cutting an estimated $9.78M.
  • Opaleye Management fully exited 4D Molecular Therapeutics in Q3 2024, selling an estimated $7.26M.
  • Opaleye Management's ten largest holdings make up 73% of its $600M portfolio in Q3 2024.
  • Opaleye Management opened 6 new positions and closed 13 in Q3 2024.
  • Opaleye Management's portfolio value rose 37% quarter-over-quarter to $600M.

Based on Opaleye Management's 13F filing for Q3 2024, filed 14 Nov 2024.